Posted by Michael Wonder on 21 Apr 2026
European Commission approves Merck’s Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus lower respiratory tract disease in infants during their first RSV season
17 April 2026 - Merck announced today that the European Commission has approved Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates (newborns) and infants during their first RSV season.
Enflonsia is contra-indicated for infants with hypersensitivity to the active substance or any of its excipients.
